Predictive role of hand-foot syndrome in patients receiving first-line capecitabine plus bevacizumab for HER2-negative metastatic breast cancer.

导出 OA

翻译打印收藏纠错

作者： Christoph,Zielinski ^[1] ; Istvan,Lang ^[2] ; Semir,Beslija ^[3] ; Zsuzsanna,Kahan ^[4] ; Moshe J,Inbar ^[5] ; Salomon M,Stemmer ^[6] ; Rodica,Anghel ^[7] ; Damir,Vrbanec ^[8] ; Diethelm,Messinger ^[9] ; Thomas,Brodowicz ^[10]

作者单位： Clinical Division of Oncology, Department of Medicine I and Comprehensive Cancer Center, Medical University Vienna - General Hospital, Waehringer Guertel 18-20, A-1090 Vienna, Austria. ^[1] Central European Cooperative Oncology Group (CECOG), Waehringer Guertel 18-20, A-1090 Vienna, Austria. ^[2] National Institute of Oncology, Ráth György u. 7-9, H-1122 Budapest, Hungary. ^[3] Institute of Oncology, Clinical Center, University of Sarajevo, Bolnicka 27, 71000 Sarajevo, Bosnia and Herzegovina. ^[4] Department of Oncotherapy, University of Szeged, Korányi fasor 12, H-6720 Szeged, Hungary. ^[5] Oncology Division, Tel Aviv Sourasky Medical Center, 6 Weizman Street, Tel Aviv 64239, Israel. ^[6] Davidoff Center, Rabin Medical Center, Kaplan Street, Petah Tikva 49100, Israel. ^[7] University of Medicine and Pharmacy Bucharest, Soseaua Fundeni, Nr 252, Sector 2, Bucharest 022328, Romania. ^[8] Department of Medical Oncology, University Hospital Zagreb-Rebro, Medical University of Zagreb, Kispaticeva 12, 10000 Zagreb, Croatia. ^[9] IST GmbH, Soldnerstrasse 1, 68219 Mannheim, Germany. ^[10]